Cogent Biosciences, Inc.
COGT
$39.16
$0.180.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.58% | -24.73% | -23.37% | -24.95% | -27.54% |
| Total Depreciation and Amortization | 4.56% | 7.13% | 6.75% | 39.55% | 28.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 149.49% | -20.63% | 13.20% | 61.80% | -56.98% |
| Change in Net Operating Assets | -64.46% | 204.15% | -45.38% | -122.88% | 94.41% |
| Cash from Operations | -23.66% | -27.73% | -26.62% | -37.46% | -36.90% |
| Capital Expenditure | 76.79% | 11.49% | -681.43% | 76.19% | -131.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -356.31% | 110.70% | 6,177.02% | 471.51% | 166.88% |
| Cash from Investing | -357.61% | 110.53% | 6,545.50% | 487.96% | 166.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37,063.78% | -93.79% | -88.33% | -- | -37.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 93.97% | -- | -- | -- |
| Cash from Financing | 34,734.46% | 18,548.05% | -88.33% | -- | -37.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.26% | 101.25% | -82.88% | 103.34% | 106.92% |